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Personalized Medicine in Context: Social Science Perspectives  
 
Introduction    
 
In the 1990s, the scientific and popular press heralded the emergence of a new 
paradigm in drug discovery and development called pharmacogenomics (pgmx). This 
science would produce a new generation of ‘personalized medicines’ utilizing 
information about individuals’ genotypes to make more effective and safer drugs. As 
well as capturing the interest of scientists, policymakers and journalists, the field of 
personalized medicine has also been of immense interest to social scientists who 
research new innovations in health and biomedicine. Social science has mapped 
industry involvement in pgx and ‘personalized medicine’ since the 1990s, identifying 
the visions that have guided development in this field and reflected on the broader 
social and economic contexts in which pgx has appeared. The clinical adoption and 
the challenges of pgx testing becoming a standard healthcare service have also been 
documented by careful examination of clinicians’ own practices, and social science 
has also explored public perspectives on pgx and the potential implications of patient 
stratification.  The purpose of this article is to review this research and its contribution 
to an understanding of personalized medicine. It will summarize some of the most 
important findings to date, and reflect on the future research agenda.   
 
Personalized Medicine as a Vision  
 
One of the key roles of social science research has been to map the construction of 
scientific fields of inquiry over time and the means by which these fields attract their 
supporters. Central to this undertaking has been the study of language not for its own 
sake but for understanding its practical significance. Hedgecoe argues that the 
adoption of the term pgmx did not describe an area of research distinct to that of 
pharmacogenetics (pgx) which had been in existence for forty years, but served as a 
rhetorical device to gain support and investment by linking it to the Human Genome 
Project (1). This is not to deny that important technical changes had taken place such 
as the development of SNP databases and chips to genotype individuals to identify 
genetic variation. However, it is of note that the term pgmx only first appeared with 
the announcement of an alliance between Genset and Abbot Pharmaceuticals in 1997 
and so became associated more closely with the commercial potential of the study of 
the role of genetic variability in drug response in drug development. The two terms 
pgx and pgmx have continued to be used and their exact meanings disputed and 
debated by scientists and others (2).  
 
The potential contribution of pgmx was described as producing ‘a new generation of 
personalized medicines’ -- drugs aimed at the individual as opposed to the ‘average 
person’ (3). Since that time, ‘personalized medicine’ (in the singular now) has proven 
to be a highly popular term that easily conveys to a range of audiences what genomics 
has to offer medicine and healthcare in the twenty-first century. However, clinicians 
had used the term personalized medicine since the early 1950s to describe a patient-
centred practice that focused on the 'art’ of clinical judgement and was often hostile to 
technology in medicine (4). The term personalized medicine has also been 
controversial: some claim that it promises more than can be delivered because 
individualized therapy can only be truly realized in a biopsychosocial paradigm while 
pgmx is a biomechanistic concept that is instead concerned with the stratification of 
patient populations (5). Recently, certain actors have preferred other expressions such 
as stratified medicine as a more accurate description of how drugs are targeted at 
groups as opposed to individuals (6).  
 
Building on this interest in language, social scientific analysis of emerging 
biotechnologies has also proceeded with understanding that the visions of social 
actors such as scientists can shape technological outcomes by attracting allies and 
their resources to support work to realize these visions. Therefore the study of visions 
has been central to a thorough examination of how a technology is constructed and 
then translated into everyday use. This approach has been adopted by social scientists 
in relation to pgx (7, 8). Smart and Martin show that there were multiple and 
potentially competing pathways for pharmacogenetics to develop, which included: (i) 
discovering new ‘pgmx’ drugs aimed at genomic sub-populations; (ii) the 
identification at later clinical development stages of ‘good responders’ for new drugs; 
(iii) use of efficacy data in the marketing of both new and existing drugs; (iv) pre-
prescription screening to identify patients at risk of ADRs; and (v) pre-prescription 
screening to identify ‘good responders’ (8). Smart and Martin’s study investigated the 
level of support from the biotech and pharma industry for each of these ‘visions’ in 
order to assess their prospects, interviewing industry leaders and analyzing published 
data on publicly announced collaborations. They conclude that there was significant 
interest in the potential of pharmacogenetics to aid in new drug discovery and 
development (i, ii), but there were barriers to applying pgx in relation to already 
licensed drugs. However, there were some exceptions, most notably the HIV/AIDS 
drug Abacavir (Ziagen) developed by GlaxoSmithKline; it was also clear that some 
specialist diagnostic developers saw opportunities to develop and market diagnostic 
tests for existing drugs.     
 
Recent analysis of FDA data indicates that just over 10% of the 385 drugs licensed in 
the period 1998-2011 had pgx biomarker data included in their labels at the time of 
their approval (9). Only three drugs – Herceptin®, Xalkori® and Zelboraf® – were 
approved by the FDA as ‘combination products’ of co-developed drugs and 
companion diagnostics. Of the drugs listed by the FDA as having pgx biomarker data 
in their labels the majority are already licensed drugs for which this data is included in 
the main to improve their safer use by clinicians and patients (9). Therefore, the 
evidence is that significant headway has been made on pre-prescription screening on 
drug safety grounds.  Where drugs have been approved with biomarker data to guide 
their use by clinicians, the majority have been cancer therapies. The wider application 
of pgx to other therapeutic areas is for now unclear.   
 
Personalised Medicine in Clinical Practice  
 
Social science research has followed personalised medicine into clinical practice to 
document how pre-prescription testing is mobilised to identify patients who are likely 
to respond well to particular drugs and those that are at increased risk of adverse drug 
responses (10, 11). At present, this approach is almost exclusively limited to 
secondary care where the increased complexity, cost and toxicity of therapies makes a 
trial-and-error model of prescribing inappropriate. Oncology is of particular note as a 
clinical specialism in which pharmacogenetic approaches to medicines and patient 
bodies have become fairly well routinised. As noted above, 42% (n=36) of the current 
117 biomarker associations identified in FDA-approved drugs pertain to this 
therapeutic area. Within this field, the breast cancer drug Herceptin® has repeatedly 
been drawn on as an example of the highly successful integration of personalized 
medicine into routine clinical use. Herceptin is only effective in the 25-35% of breast 
cancer patients whose tumours over-express the human epidermal growth receptor 2 
(HER2) protein as a result of gene amplification. Given this, pre-prescription testing 
of the breast tumour for HER2+ status can determine whether Herceptin is an 
appropriate therapy option. Notwithstanding the debate as to whether Herceptin ought 
to be considered pgx drug at all (since it is targeted at the tumour not the genotype of 
the patient), its adoption is noteworthy for a number of reasons. For example, the 
media played a central part in debates about the extension of Herceptin’s license for 
the treatment of early stage breast cancer (12; 13). Moreover, by funding HER2 tests 
prior to Herceptin’s approval, Roche gained  widespread professional support from 
oncology practitioners and overcame the previously conservative British oncology 
testing culture. This experience provides a useful insight into understanding the 
nuances of testing cultures across different clinical specialisms in Britain and 
elsewhere (14;11). 
  
Further research on clinical cultures has shown that the divergent adoption of pgx 
testing across different clinical specialisms is less about conservatism or resistance 
than the perceived ‘clinical usefulness’ of tests in specific clinical settings. Four social 
aspects of clinical practice which contribute to understandings of pgx tests as useful 
or otherwise; (i) the differences between disease classifications in scientific research 
and clinical practice; (ii) the potentially wide ranging familial implications of test 
results; (iii) complexity around which clinical department is liable for financing 
pharmacogenetic tests and/or care for adverse events; and (iv) the precedence given to 
clinicians’ diagnostic opinions over tests results where these two differ ( 15,16, 17). 
This final point has also been discussed in relation to familial hypercholesterolemia 
where researchers found that practitioners involved in diagnosis understood genetic 
test results as less useful than other information, namely cholesterol tests (18).  
 
As an example of this clinical usefulness framework in practice the Alzheimer’s drug 
Tacrine is commonly mobilised as an example antithetical to Herceptin where the 
integration of pgx testing has been significantly stalled. Briefly, during the 1990s 
variations in response to Tacrine were linked to changes on the APOE gene (APOE4) 
which was also linked with increased risk of late-onset Alzheimer’s disease. Within 
the scientific community, however, conflicting results were presented with some 
researchers understanding APOE4 as central to Tacrine response and others being 
more sceptical about the links between Tacrine and genotype (19; 20). Moreover, pre-
prescription tests for Tacrine would also highlight a genetic susceptibility to 
Alzheimer’s which clearly has wide-ranging familial implications. Pgx tests for 
Tacrine response were, then, considered limited in their clinical usefulness given that 
the scientific community could not produce quantifiable conclusions about the 
APOE/Tacrine link for use in clinical practice and given the familial implications of 
identifying the presence of an increased Alzheimer’s risk factor (15).  
 
Social science has shown how the cases of Herceptin and Tacrine highlight the 
complex nature of the integration of pgx testing into clinical practice where the 
‘micro’ world of everyday work, politics and cultures of clinical practises become as 
important as, and intertwined with, the ‘macro’ politics of medicine vis-à-vis 
regulation and funding. In bringing the importance of these social and cultural issues 
to the fore, questions of personalized medicine in clinical practice become somewhat 
more complex than simply seeing clinician education and resources as the principal 
‘barriers’ to the uptake of pgx in clinical practice (21;22).  
 
Personalised Medicine and Patients  
 
As well as clinicians’ perspectives on the clinical usefulness of pgx testing, public 
understandings of their clinical usefulness are also central to their uptake and 
routinization within healthcare practices (23).  
 
Patient Expectations: Social scientific research has indicated that there can be a 
disjuncture between patients’ high expectations of pgx and practitioners’ relative 
reluctance to deliver pgx services (24). A study of lay peoples’ perspectives on pgx 
found that whilst most respondents were generally positive about the potential 
improvements to patient outcomes and experiences, its perceived preventative, rather 
than curative, nature could weaken the chances of pgx being adopted (25).  
 
Privacy and Confidentiality: Surveys of public perception highlight concerns 
around privacy and confidentiality of results as a factor which could restrict the 
clinical usefulness of pgx from the patient’s perspective (26). This concern is echoed 
by qualitative research which found that although Australian consumers were anxious 
about, and keen to minimise, side effects of drugs, they were sceptical about whether 
their genetic data could be securely stored (27). Questions of insurance and 
employment discrimination also features prominently in social scientific analyses of 
(pharmaco)genetics. Although anti-discrimination legislation has been passed such as 
Genetic Information Non-discrimination Act (2008) in the US which prevents insurers 
and employers using genetic information in a discriminatory way, American 
employers can still request all health records as a condition of employment (28).  
 
Familial Nature of Genetic Information: The familial aspect of privacy and 
confidentiality in pgx practice has also been examined. Although the decision to 
undergo any (pharmaco)genetic test should be the decision of the individual patient 
alone, the results are necessarily familial and, as such the potential risks to other 
family members ought to be taken into consideration during any genetic testing 
process (29). Others have identified the nature of medicine itself as family or 
community medicine in that individuals cannot easily be separated from their social or 
cultural environments given the genetic ties (and responsibilities) with which they are 
bound (16; 30; 31). In a seminal report of the ethical challenges of pgx, the Nuffield 
Council on Bioethics (2003) noted that such decisions around informing family 
members cannot be arbitrarily legislated against and, instead, recommended that 
decisions about informing family members of potential genetic risks identified by test 
results should be taken by the healthcare practitioner based on the circumstances of 
each individual case (32).  
 
Implications of Patient Stratification: Another issue that has been prominent is 
social scientific analyses of pgx is the extent to which stratification practises risk 
replicating issues of social injustice and healthcare inequality that have been a central 
concern of medical sociology. Social scientists have also contemplated whether 
stratification may also lead to the emergence of therapeutic ‘orphan populations’ with 
limited access to new and more effective treatments (10, 33, 34). This may be a result 
of their genetic make-up falling outside of the most common genotypes where 
discovering effective therapies is challenging using available technology or because 
the genetically-defined subpopulation to which they belong is too small to be 
economically attractive as a potential market for pharmaceutical companies. Where 
drugs are developed for these small patient subpopulations, the probability is that they 
will be extremely expensive, thus reproducing questions of equality and access (33). 
 
While pgx offers a way to stratify patients by genotype, fears have been expressed 
about using proxies such as race/ethnicity to target the development and marketing of 
drugs (35, 36). Central to many of the sociological debates about race and pgx has 
been the congestive heart disease drug BiDil®, which was licensed by the FDA in 
2005 for use in (self-identifying) African-American patients only. Its appearance 
prompted concerns that by characterizing drugs and drug responses along racial lines, 
health differences would be attributed purely to biological factors and thus 
marginalize social inequalities, such as education and housing, which can have 
significant effects on health (37).  
 
On a global scale, it has been questioned how useful pgx practises will be for low- 
and middle-income countries where access to basic healthcare provision is limited 
(38). Given that subscription to pgx medicine will involve a ‘sophisticated’ testing 
and medical information technology infrastructure, the extent to which it can be 
successfully integrated into medical practice in poorer countries is questionable (33). 
In this way, current global inequalities of access to contemporary biomedicine may be 
reproduced where patients in the wealthy developed world routinely use genetic 
information to increase the safety and efficacy of medicines whilst healthcare in the 
developing world remains characterised by risk (38).  
 
Future Research  
 
To conclude this short review, we highlight a number of new directions for social 
science research. We endorse the suggestions made by Hogarth et al for further study 
of the role of drug regulators and activities in biomarker patenting (39). To that we 
would add the following: (i) Further investigation of the different professional roles in 
delivering pgx as a healthcare service both now and in the future; at present there is 
something of an implicit assumption that doctors are, and will be, the primary 
practitioners carrying out pgx testing. We suggest that it is important for social 
scientists to examine this assumption more fully and explore the potential role of 
other professional groups like nurses and pharmacists. (ii) To develop the 
opportunities offered by ‘big data’ to research more fully the patterns of pgx uptake in 
healthcare services and (iii) to engage in an interdisciplinary dialogue with health and 
biomedical scientists on how personalization could be elaborated in a way that 
encompasses biomechanistic and biopsychosocial aspects of patient care and the 
structural determinants of health inequalities in society. Such an interdisciplinary 
approach to the multiple biological and social determinants of health inequalities 
seems apposite given the increasing interest in epigenetics.   
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